Lambropoulos A F, Foka Z, Makris M, Daly M, Kotsis A, Makris P E
Biology Department, Medical Faculty, Aristotle University of Thessaloniki, Greece.
Blood Coagul Fibrinolysis. 1997 Nov;8(8):485-9.
We studied 172 Greek patients (72 men aged 44.0 +/- 16.7 years and 100 women aged 46.5 +/- 14.1 years) with an unexplained thrombophilic tendency. One hundred and four apparently healthy persons (63 men aged 34.2 +/- 10.0 years and 41 women aged 37.1 +/- 13.3 years) were included as a control group. We performed the activated protein C resistance (APC-r) test using a clotting test (Chromogenix kit), detection of factor V Leiden using polymerase chain reaction (PCR)-restriction fragment length polymorphisms and measurement of thrombin-antithrombin complexes (TAT) and prothrombin fragment 1 + 2 (F1 + 2) levels with an immunoenzymatic assay. The normal range for the APC-r test (> 2.12) was determined from the controls. The factor V Leiden mutation was found in 31.9% of all the patients tested, in 28.1% of the unrelated patients with documented thrombophilic tendency of unknown origin and in 4.8% of the healthy controls. The APC-r test had a sensitivity of 0.42 and a specificity of 0.91 for the detection of factor V Leiden. Furthermore, we found no significant difference in levels of TAT and F1 + 2 between patients with and without the mutation and there was no correlation between aPC-r values and levels of TAT and F1 + 2.
我们研究了172名有不明原因血栓形成倾向的希腊患者（72名男性，年龄44.0±16.7岁；100名女性，年龄46.5±14.1岁）。104名明显健康的人（63名男性，年龄34.2±10.0岁；41名女性，年龄37.1±13.3岁）被纳入作为对照组。我们使用凝血试验（发色底物试剂盒）进行活化蛋白C抵抗（APC-r）试验，采用聚合酶链反应（PCR）-限制性片段长度多态性检测因子V莱顿突变，并通过免疫酶测定法测量凝血酶-抗凝血酶复合物（TAT）和凝血酶原片段1 + 2（F1 + 2）水平。APC-r试验的正常范围（> 2.12）由对照组确定。在所有接受检测的患者中，31.9%发现有因子V莱顿突变，在有不明来源血栓形成倾向记录的非亲属患者中，28.1%发现有该突变，在健康对照组中，4.8%发现有该突变。APC-r试验检测因子V莱顿突变的敏感性为0.42，特异性为0.91。此外，我们发现有突变和无突变患者之间TAT和F1 + 2水平无显著差异，且aPC-r值与TAT和F1 + 2水平之间无相关性。
